TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31394314

Group type: EXPERIMENTAL
Intervention: Bouncing Image Training Task (BITT) - daily sessions for one week
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 113
Study: 27093861

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy schedule with 51.3 Gy in 18 fractions (3 fractions per week)
Number of subjects: 80
Study: 25662989

Group type: EXPERIMENTAL
Intervention: MN-RSh (RSh group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: MN-CAS (CAS group)
Number of subjects: 45
Study: 23397236

Group type: EXPERIMENTAL
Intervention: Young adult participants exposed to misleading suggestions from older adult confederates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adult participants exposed to misleading suggestions from older adult confederates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Young and older adult participants
Number of subjects: 0
Study: 20079480

Group type: EXPERIMENTAL
Intervention: MIST‐VR
Number of subjects: 46

Group type: COMPARATOR
Intervention: D‐Box
Number of subjects: 46
Study: 18211118

Group type: EXPERIMENTAL
Intervention: SFC 50 microg/100 microg
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 16939559

Group type: EXPERIMENTAL
Intervention: Decreasing mean HbA1c from 9.5% to 8.0%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreasing mean HbA1c from 8.0% to 7.0%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreasing mean HbA1c from 7.0% to 6.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential reduction scenarios
Number of subjects: 0

Group type: COMPARATOR
Intervention: No reduction in HbA1c
Number of subjects: 0
Study: 14661000

Group type: EXPERIMENTAL
Intervention: Model 6944 (small electrode surface area)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Model 6942 (conventional sized electrode surface area)
Number of subjects: 542
Study: 10960626

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Estrogen 0.625 mg/day
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 1618254

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 12
Study: 6599665

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (n = 87)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Sodium restriction intervention (n = 169)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control group (continue medication)
Number of subjects: 496
Study: 30115584

Group type: EXPERIMENTAL
Intervention: Weight management and physical activity intervention including self-monitoring tools, a single exercise counseling home visit, and up to 11 telephone calls from a health coach over 20 weeks.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Self-directed control group received the same tools and materials but no home visit or coaching calls.
Number of subjects: 15
Study: 30252192

Group type: EXPERIMENTAL
Intervention: Telenursing protocol with home monitoring during a 12 week implementation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Telenursing protocol with home monitoring
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Telenursing with home monitoring
Number of subjects: 43
Study: 26295966

Group type: EXPERIMENTAL
Intervention: Prophylactic CPAP for 20 minutes via face mask
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standardized care without CPAP
Number of subjects: 259
Study: 25454878

Group type: EXPERIMENTAL
Intervention: CSL's TIV
Number of subjects: 1474
Study: 22735103

Group type: EXPERIMENTAL
Intervention: Home based early intervention delivered by specially trained community nurses (8 home visits)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 667
Study: 21090831

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg once daily for a median follow-up of 1.9 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18062765

Group type: EXPERIMENTAL
Intervention: Clinic-based exercise intervention
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 32
Study: 16055639

Group type: EXPERIMENTAL
Intervention: Chronic prejudice expectations in a diary study of college roommates (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Situationally induced prejudice expectations in a laboratory interaction (Study 2)
Number of subjects: 0
Study: 12014167

Group type: EXPERIMENTAL
Intervention: Opalescence 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rembrandt 10%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo agent
Number of subjects: 0
Study: 10575333

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg/day p.o. plus standard therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 169
Study: 8720886

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 100
Study: 1907675

Group type: EXPERIMENTAL
Intervention: 22.5% BCAA solution
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 45% BCAA solution
Number of subjects: 80
Study: 6125625

Group type: EXPERIMENTAL
Intervention: Beta-receptor blocker (10 mg of bunitrolol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31512148

Group type: EXPERIMENTAL
Intervention: CardioMEMS (direct pulmonary pressure monitor system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active pulmonary pressure-guided management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30744654

Group type: EXPERIMENTAL
Intervention: Maple Water (MW)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (maple-flavored bottled water)
Number of subjects: 26
Study: 28379623

Group type: EXPERIMENTAL
Intervention: 100 mg once-daily aspirin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 100 mg twice-daily aspirin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 200 mg once-daily aspirin
Number of subjects: 37

Group type: COMPARATOR
Intervention: 100 mg once-daily aspirin (control group)
Number of subjects: 37
Study: 28027636

Group type: EXPERIMENTAL
Intervention: Nutrition education group sessions (12 weekly 75-min sessions)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (leaflets on evidenced-based nutrition information)
Number of subjects: 238
Study: 24408122

Group type: EXPERIMENTAL
Intervention: Avosentan
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1392
Study: 23273217

Group type: EXPERIMENTAL
Intervention: Multidisciplinary transmural rehabilitation programme (duration: 2 to 6 months) consisting of neurorehabilitation treatment, empowerment training, and stroke education.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care in the nursing home and after discharge (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary transmural rehabilitation programme (duration: 2 to 6 months).
Number of subjects: 0
Study: 21042404

Group type: EXPERIMENTAL
Intervention: 1 bite of Anopheles stephensi mosquitoes infected with P. falciparum
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3 bites of Anopheles stephensi mosquitoes infected with P. falciparum
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 5 bites of Anopheles stephensi mosquitoes infected with P. falciparum
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All groups (1, 3, or 5 bites)
Number of subjects: 18
Study: 17923398

Group type: EXPERIMENTAL
Intervention: Tricutan
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15990659

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 336

Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Heat
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation (EMS)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Moderate-to-severe neck disability at baseline
Number of subjects: 336
Study: 12483050

Group type: EXPERIMENTAL
Intervention: Noncuffed, percutaneously inserted central venous catheters (CVCs)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Colonized CVCs
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: CVCs causing BSIs
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Noncolonized CVCs
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Local inflammation
Number of subjects: 1263
Study: 9445119

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 98
Study: 7623294

Group type: EXPERIMENTAL
Intervention: Tizanidine (150 micrograms kg‐1 orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1777653

Group type: EXPERIMENTAL
Intervention: 5 mg glipizide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no glipizide)
Number of subjects: 18
Study: 6263442

Group type: EXPERIMENTAL
Intervention: Screened group (lung cancer screening every four months for six years)
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 4500
Study: 31523022

Group type: EXPERIMENTAL
Intervention: Music therapy during surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (without music during surgery)
Number of subjects: 120
Study: 30972655

Group type: EXPERIMENTAL
Intervention: Progressive upper limb exercises and muscle relaxation training (PULE‐MRT) plus routine nursing care for 6 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine nursing care for 6 months
Number of subjects: 102
Study: 28396999

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 6045

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6045
Study: 25666417

Group type: EXPERIMENTAL
Intervention: 200mg RGC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 400mg RGC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined RGC-treated group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23415472

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin 20 IU BID for 3 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (in a small group of inpatients)
Number of subjects: 28
Study: 21235810

Group type: EXPERIMENTAL
Intervention: NexGen LPS with navigation
Number of subjects: 90

Group type: COMPARATOR
Intervention: NexGen LPS without navigation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Stryker Scorpio PS with navigation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (NexGen LPS without navigation)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Navigation (general)
Number of subjects: 90
Study: 19808442

Group type: EXPERIMENTAL
Intervention: CPVA‐1 group (circumferential pulmonary vein ablation with linear lesions along the LA roof)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CPVA‐2 group (circumferential pulmonary vein ablation with LA posterior wall isolation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of CPVA‐1 and CPVA‐2 groups
Number of subjects: 120
Study: 17154160

Group type: EXPERIMENTAL
Intervention: Saforis (glutamine) powder, 3 times/day during Treatment Cycle 1
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo, 3 times/day during Treatment Cycle 1
Number of subjects: 326
Study: 15466766

Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg) plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo plus Prednisone (25 mg/d tapered to 0 mg/d within 24 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Methotrexate (10 mg) plus Prednisone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo plus Prednisone
Number of subjects: 72
Study: 11244365

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (1 puff three times daily per nostril for 15 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 89
Study: 9647686

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divided attention conditions
Number of subjects: 0
Study: 8018037

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Combined groups (Phenytoin and Carbamazepine)
Number of subjects: 82
Study: 2644830

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 91
Study: 861375

Group type: EXPERIMENTAL
Intervention: Total nodal radiotherapy with combination chemotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Total nodal radiotherapy without combination chemotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Total nodal radiotherapy
Number of subjects: 52
Study: 31464082

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Coblation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both TORS and coblation
Number of subjects: 85
Study: 27682442

Group type: EXPERIMENTAL
Intervention: Tailored repositioning and a turning and repositioning system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized incontinence care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25796966

Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavior Therapy for Insomnia (CBTI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 32
Study: 22889717

Group type: EXPERIMENTAL
Intervention: Real GSM-EMFs exposure (45 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham GSM-EMFs exposure (45 min)
Number of subjects: 10
Study: 21511523

Group type: EXPERIMENTAL
Intervention: Visual motion adaptation using a random dot kinematogram display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline threshold TMS intensity
Number of subjects: 0
Study: 19703236

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with professional plaque control (PPC) (twice a week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with chlorhexidine rinsing (CHX) (twice a day)
Number of subjects: 60
Study: 17902187

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI) 25 mg every 14 days (60% of patients)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 52
Study: 15499822

Group type: EXPERIMENTAL
Intervention: Reminders of mortality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control topic (aversive topic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judicial instructions manipulating nullification proneness
Number of subjects: 0
Study: 11595992

Group type: EXPERIMENTAL
Intervention: Chlorhexidine preparation of skin before and during catheterization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scheduled replacement of catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surveillance for nosocomial infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal method of aseptic insertion for central venous catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impregnation of catheter and/or hub surfaces with antiseptics
Number of subjects: 0
Study: 9010901

Group type: EXPERIMENTAL
Intervention: Interactive program (shortened lecture, clinical practice, small group feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional didactic teaching program
Number of subjects: 0
Study: 7886282

Group type: EXPERIMENTAL
Intervention: Blocked order of trials
Number of subjects: 36

Group type: COMPARATOR
Intervention: Serial order of trials
Number of subjects: 36
Study: 2889528

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28488021

Group type: EXPERIMENTAL
Intervention: Cue exposure training (CET + TAU), N = 40
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual (TAU only), N = 18
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall subjects
Number of subjects: 58
Study: 27241895

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400mcg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 26233335

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (84 μg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (84 μg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CNS effects of dexmedetomidine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cardiovascular effects of dexmedetomidine
Number of subjects: 6
Study: 23483174

Group type: EXPERIMENTAL
Intervention: Primary care management of obstructive sleep apnea
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual care in a specialist sleep center
Number of subjects: 155
Study: 21120832

Group type: EXPERIMENTAL
Intervention: Sound Sense™ hearing conservation program
Number of subjects: 16
Study: 18212347

Group type: EXPERIMENTAL
Intervention: Early reconstruction (within 21 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Delayed reconstruction (beyond 6 weeks)
Number of subjects: 69
Study: 16763748

Group type: EXPERIMENTAL
Intervention: 84 mg soy isoflavones
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 126 mg soy isoflavones
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0 mg soy isoflavones)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Urinary total deoxypyridinoline
Number of subjects: 90
Study: 14623802

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 13
Study: 10890665

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intermittent positive-pressure ventilation (IPPV)
Number of subjects: 34
Study: 8717600

Group type: EXPERIMENTAL
Intervention: Satisfaction with Decision (SWD) scale
Number of subjects: 0
Study: 1315211

Group type: EXPERIMENTAL
Intervention: WR-2721 plus radiation therapy (WR + RT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiation therapy (RT) only
Number of subjects: 100
Study: 3886724

Group type: EXPERIMENTAL
Intervention: Doxepin (10 mg three times a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diphenhydramine (25 mg three times a day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diphenhydramine
Number of subjects: 50
Study: 30953892

Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (G‐IPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study: 29304065

Group type: EXPERIMENTAL
Intervention: iTBS (excitatory theta-burst stimulation) over the left DLPFC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: cTBS (inhibitory theta-burst stimulation) over the right DLPFC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: cTBS (inhibitory theta-burst stimulation) over the left DLPFC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: iTBS (excitatory theta-burst stimulation) over the right DLPFC
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 51
Study: 28202845

Group type: EXPERIMENTAL
Intervention: 2.50 g ALA-DAG
Number of subjects: 38

Group type: COMPARATOR
Intervention: 1.25 g ALA-DAG
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (0.00 g ALA-DAG)
Number of subjects: 38
Study: 25445075

Group type: EXPERIMENTAL
Intervention: CBM-I intervention targeting early adolescents' cognitive biases related to social anxiety (Child-only condition)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CBM-I intervention targeting parents' biases associated with intrusive behavior (Parent-only condition)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CBM-I intervention targeting both youth and parents' biases in tandem (Combo condition)
Number of subjects: 18
Study: 23093337

Group type: EXPERIMENTAL
Intervention: Low-dose dietary potassium alkali supplementation
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: High-dose dietary potassium alkali supplementation
Number of subjects: 266

Group type: COMPARATOR
Intervention: Dietary sodium chloride intake
Number of subjects: 266

Group type: COMPARATOR
Intervention: Dietary potassium intake
Number of subjects: 266
Study: 20019087

Group type: EXPERIMENTAL
Intervention: Zarzio (1 microg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zarzio (2.5 microg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zarzio (5 microg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zarzio (10 microg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zarzio (5 microg/kg i.v.)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zarzio (300 or 480 microg) in breast cancer patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neupogen (reference product)
Number of subjects: 24
Study: 18594001

Group type: EXPERIMENTAL
Intervention: 500 mg/m² pemetrexed (P500)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 1,000 mg/m² pemetrexed (P1000)
Number of subjects: 216
Study: 17189542

Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (EST)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline control (CON)
Number of subjects: 12
Study: 12540351

Group type: EXPERIMENTAL
Intervention: Physical training (two sessions a week for 16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20